Leaders at GlaxoSmithKline (GSK) and Innoviva Inc. recently announced the results of the new Salford Lung Study (SLS) in Chronic Obstructive Pulmonary Disease (COPD), which shows that using Relvar Ellipta instead of traditional treatments gives COPD patients greater relief.
The study showed that Relvar Ellipta was effective when patients used it on a daily basis in a clinical study. The patients experienced a greater decline in exacerbations compared to their usual care routines.
“In this genuinely groundbreaking study, we have worked closely with the local NHS clinical community to study patients in their everyday setting,” Patrick Vallance, president of pharmaceuticals research and development for GSK, said. “To ensure the results from Salford were as robust as possible, we made a long-term financial investment in the study, including supporting local infrastructure and training. Innovation often means you have to ask challenging questions to make significant advances, and I believe this is what we have achieved in these positive results announced today.”
Traditional COPD care features long-acting muscarinic antagonists (LAMA), inhaled corticosteroids (ICS) and long-acting beta2-agonists (LABA). These are administered through monotherapy, triple or dual combinations.
“The Salford Lung Study is a very important trial to help us understand more about the medicines we prescribe on a day-to-day basis,” Jørgen Vestbo, lead investigator and professor of respiratory medicine, said. “This is an important finding; what we are seeing today is the tip of the iceberg. Over the coming months, we will understand more about the day-to-day effectiveness of FF/VI and how treatment choice, patient behavior, co-morbidities and other factors combine to influence COPD outcomes. This has been a highly collaborative effort to gather data that will help improve understanding about the effectiveness of respiratory medicines when used in usual clinical practice.”
